Applied Therapeutics Inc

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company which engages in the development of a pipeline of novel products. It is targeting treatments for central nervous system rare diseases and diabetic complications. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.

Earnings data Q3 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it plans to make a public offering of 3,000,000 shares of its common stock, par value $0.0001 per share, in an underwritten registered public offering. The Company expects to grant the underwriters a 30-day option to purchase up to 450,000 additional shares of its common stock.

Applied Therapeutics, Inc. Announces Offering of 3,000,000 Shares of Common Stock

Applied Therapeutics Announces Restart of Pediatric Galactosemia Study

NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the launch of Galactosemia Together, the first and only industry-led Galactosemia awareness and education campaign. Developed in partnership with the Galactosemia community, this initiative aims to address gaps in education by providing updated, reliable and credible resources to help connect, educate and support those families impacted by this disease.

Applied Therapeutics Announces Launch of Galactosemia Awareness and Education Initiative

NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced magnetic resonance spectroscopy (MRS) data on reduction of galactitol levels in the brain of Galactosemia patients treated with AT-007 in the ACTION-Galactodsemia adult study. Overall, plasma reduction in galactitol correlated with brain reduction in galactitol. There were two exceptions, which may have resulted from incomplete peak separation on the MRS scans. At the two doses which demonstrated statistically significant reduction in plasma galactitol, 20 and 40mg/kg, 3 out of 4 patients displayed substantial galactitol reduction ranging from 61.94% to 69.80% reduction from baseline.

Applied Therapeutics Announces MRS Data from ACTION-Galactosemia Study

Continued enrollment in the ARISE-HF Phase 3 global registrational study of AT-001 in Diabetic Cardiomyopathy (fatal heart disease affecting ~17% diabetics)

Applied Therapeutics Reports Third Quarter 2020 Financial Results

Treatment with AT-001 normalizes cardiac energetics and improves cardiac function in a mouse model of Diabetic Cardiomyopathy (DbCM) Treatment with AT-001 normalizes cardiac energetics and improves cardiac function in a mouse model of Diabetic Cardiomyopathy (DbCM)

Applied Therapeutics Announces Presentation of Pre-Clinical Data on AT-001 for the Treatment of Diabetic Cardiomyopathy at the American Heart Association (AHA) Scientific Sessions 2020

NEW YORK, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will present two poster presentations covering AT-007 in Galactosemia at the upcoming American Society of Human Genetics (ASHG) 2020 Annual Meeting. The presentations include animal model efficacy data and adult clinical data on the safety and biomarker efficacy of Applied Therapeutics' investigational candidate for Galactosemia, AT-007, a Central Nervous System (CNS) penetrant Aldose Reductase Inhibitor (ARI).

Applied Therapeutics to Present Data on AT-007 for the Treatment of Galactosemia at the American Society of Human Genetics (ASHG) 2020 Annual Meeting

Applied Therapeutics Inc. (APLT) closed at $22.86 in the latest trading session, marking a -0.95% move from the prior day.

Applied Therapeutics Inc. (APLT) Stock Sinks As Market Gains: What You Should Know

Applied Therapeutics Inc. (NASDAQ: APLT) shares pushed higher on Thursday after a new analyst report came out supposing massive upside for this biotech.

Could Applied Therapeutics Stock Rise 300%?

Applied Therapeutics Inc. (APLT) closed at $20.02 in the latest trading session, marking a +0.05% move from the prior day.

Applied Therapeutics Inc. (APLT) Gains As Market Dips: What You Should Know

NEW YORK, Sept.  24, 2020  (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that the U.S. Food and Drug Administration (FDA) has granted AT-007 both Pediatric Rare Disease Designation and Orphan Drug Designation for treatment of PMM2-CDG. PMM2-CDG is a debilitating rare disease caused by deficiency in the critical enzyme phosphomannomutase-2, required for systemic glycosylation of proteins. PMM2-CDG causes multiple organ failure and severe disability, resulting in approximately 20% mortality in the first four years of life.   There are currently no drugs approved to treat PMM2-CDG.

FDA Grants AT-007 Pediatric Rare Disease Designation and Orphan Designation for Treatment of PMM2-CDG

NEW YORK, Sept.  17, 2020  (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will present two poster presentations covering AT-001, a next generation aldose reductase inhibitor (ARI), in Phase 3 development for Diabetic Cardiomyopathy at the upcoming 56th Annual Meeting of the European Association for the Study of Diabetes (EASD). The presentations include data on the safety and specificity of AT-001, as well as data on mechanistic protection from cellular damage during hyperglycemia.

Applied Therapeutics to Present Data on AT-001 for Treatment of Diabetic Cardiomyopathy at 56th Annual Meeting of the European Association for the Study of Diabetes

NEW YORK, Sept.  02, 2020  (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will present at two upcoming investor conferences in September:

Applied Therapeutics to Present at Citi and Baird Investor Conferences

LOS ANGELES--(BUSINESS WIRE)---- $APLT #fraud--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Applied Therapeutics, Inc. (APLT) on Behalf of Investors

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Applied Therapeutics, Inc. (APLT) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)---- $APLT #classaction--The Law Offices of Frank R. Cruz announces an investigation on behalf of Applied Therapeutics, Inc.

The Law Offices of Frank R. Cruz Announces Investigation of Applied Therapeutics, Inc.

LOS ANGELES--(BUSINESS WIRE)---- $APLT #APLT--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Applied Therapeutics, Inc.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Applied Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

BENSALEM, Pa.--(BUSINESS WIRE)---- $APLT #fraud--INVESTOR ALERT: Law Offices of Howard G.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Applied Therapeutics, Inc.

LOS ANGELES--(BUSINESS WIRE)---- $APLT #APLT--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Applied Therapeutics, Inc.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Applied Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT) resulting from allegations that Applied Therapeutics may have issued materially misleading business information to the investing public.

EQUITY ALERT: ROSEN, A LEADING AND RANKED LAW FIRM, Announces Investigation of Securities Claims Against Applied Therapeutics, Inc. – APLT

NEW YORK, Aug. 18, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Applied Therapeutics, Inc.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Applied Therapeutics, Inc. - APLT

NEW YORK, Aug.  11, 2020  (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the second quarter ended June 30, 2020.

Applied Therapeutics Reports Second Quarter 2020 Financial Results

In the latest trading session, Applied Therapeutics Inc. (APLT) closed at $25.93, marking a +0.5% move from the previous day.

Applied Therapeutics Inc. (APLT) Gains But Lags Market: What You Should Know

Applied Therapeutics Inc. (APLT) closed the most recent trading day at $25.74, moving +1.74% from the previous trading session.

Applied Therapeutics Inc. (APLT) Outpaces Stock Market Gains: What You Should Know

During Applied Therapeutics' (APLT) upcoming Q2 earnings call, investor focus will be on the company's progress with its novel pipeline candidates targeting areas of high unmet medical need.

What to Expect for Applied Therapeutics (APLT) Q2 Earnings

Frequency Therapeutics

Green Brick Partners

Kelly Services

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

News for Applied Therapeutics Inc Stock (APLT)